ABSTRACT— We know that infections with CMV during pregnancy is also one of the most frequent threats and seious for fetuses of pregnant women . Every year in USA about 40.00 pregnant womens are affected with CMV during pregnancy . Of the 40,000 women infected approximately 6,000 to 8,000 babies will develop severe damage and permanent neurological from this infection. Another very common effect is even fetal death or neonatal death that occurs in about 10 percent of the fetus or newborn child after an intrauterine infection with CMV, neurological damage includes obstacles in the normal development of the baby, and psychological problem deficit of listening. The degree of susceptibility to CMV during pregnancy is also well established, bearing age among women and children between 40% and 80% will be susceptible (seronegative) to CMV early in pregnancy. The degree of sensitivity in early pregnancy varies by ethnic or racial group with the highest rates occurring among African – American and Hispanic populations (populations that speak Spanish) . In 1999, the Institute of Medicine issued a report on priorities for new vaccines and gave priority to the development of a CMV vaccine . This was based not only on the frequency of neurological diseases, but also in the fact that CMV is the most common cause of hearing loss in 25 percent of all hearing deficit due to an infection born with CMV . Further, CMV is a much more common cause of severe neurological hearing in childhood as it was bacterial meningitis, congenital rubella, or herpes simplex infections of nenonatal . Reviews or questions for CMV during pregnancy are important because over 90% of maternal infections with CMV during pregnancy are asymptomatic and may remain asymptomatic even in the fetus. Reviews routine serological tests for CMV pregnant women in Europe has brought many significant advantages for the understanding of CMV infection among pregnant women. Different studies show that between 40% and 60% of pregnant women are sensitive to CMV- States and of these, between 1% to 4% will acquire CMV during pregnancy, and average between 40% and 50% infected women will transmit the virus to the fetus.
The low rate of transmission (35%) occurs when maternal infection is in the first quarter, and as the pregnancy develops, the transmission rate increases to 73 percent for women who get CMV infections in the third quarter . Approximately one third of infants infected in the uterus will have symptoms or develop serious nerve damage .
Keywords — CMV, pregnancy, abortion, primary sterility, bacterial meningitis, neurological damage, congenital rubella, or herpes simplex infections of nenonatal,